The Journal of Korean Medicine (대한한의학회지)

The Society of Korean Medicine (대한한의학회)
권호 표지
DOI QR코드

DOI QR Code

Correlation Analysis of Organic Acid Comprehensive Profile Markers with Chemotherapy Induced Peripheral Neuropathy in Cancer Patients

항암제 유발 말초신경병증환자와 유기산검사 마커와의 상관성 연구

  • Park, Ji Hye (East West Cancer Center, Dunsan Korean Medicine Hospital of Daejeon University) ;
  • Sung, Simon SangYup (SUNIN BIO) ;
  • Lee, Jin Sun (Department of surgery, Chungnam National University Hospital) ;
  • Yoo, Hwa Seung (East West Cancer Center, Dunsan Korean Medicine Hospital of Daejeon University)
  • 박지혜 (대전대학교 둔산한방병원 동서암센터) ;
  • 성상엽 (선인바이오) ;
  • 이진선 (충남대학교병원 외과) ;
  • 유화승 (대전대학교 둔산한방병원 동서암센터)
  • Received : 2017.02.28
  • Accepted : 2017.03.24
  • Published : 2017.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives: The purpose of this study is to evaluate the urinary organic acid comprehensive profile for chemotherapy induced peripheral neuropathy (CIPN). Methods: Participants are 66 patients with CIPN who had symptom (Visual analog scale ${\geq}30mm$, Eastern Cooperative Oncology Group ${\leq}2$). Participants were tested with organic acid comprehensive profile markers. Results: Positive Correlation was observed in the neurotransmitter metabolism markers, N-methyl-D-aspartate (NMDA) modulators markers, detoxification markers, energy production markers, amino acid metabolism markers, and intestinal dysbiosis markers. Especially, all the neurotransmitter metabolism markers were showed positive rate of 44%. In addition, neuro-endo-immune was associated with energy metabolism (mitochondrial dysfunction) in CIPN of cancer patient. especially detoxification, intestinal bacterial hyperplasia, vitamin deficiency (folate, complex B group, vitamin C). Conclusions: Significant urinary organic acid comprehensive profile results were obtained in cancer patients who induced peripheral neuropathy by chemotherapy.

Keywords

References

  1. Choie MH, Jeong IS, Jeong TY, Kim KS, Yoo HS. Effects of reflexology foot massage to improve quality of life and reduce anxiety for hospitalized cancer patients undergoing chemotherapy or radioisotope therapy. J Korean Trad Oncol. 2009;14:61-74.
  2. Windebank AJ, Grisold W. Chemotherapy -induced neuropathy. J Peripher Nerv Syst. 2008;13(1):27-46. https://doi.org/10.1111/j.1529-8027.2008.00156.x
  3. Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C. Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. European journal of cancer. 2008;44(11):1507-15. https://doi.org/10.1016/j.ejca.2008.04.018
  4. Housheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Emin Oncol. 2006;33; 15-49.
  5. Ajani JA, Welch SR, Raber MN, Fields WS, Krakoff IH. Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest. 1990;8:147-59. https://doi.org/10.3109/07357909009017560
  6. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207-14. https://doi.org/10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6
  7. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-55. https://doi.org/10.1097/00000421-198212000-00014
  8. Cavaletti G, Jann S, Pace A, Plasmati R, Siciliano G, Briani C, et al. Multi-center assessment of he Total Neuropathy Score for chemotherapy-induced peripheral eurotoxicity. J Peripher Nerv Syst. 2006;11:135-41. https://doi.org/10.1111/j.1085-9489.2006.00078.x
  9. Kwak MK, Kim EJ, Lee ER, Kwon IG, Hwang MS. Characteristics and Quality of Life in Patients with Chemotherapy-Induced Peripheral Neuropathy. Journal of Korean oncology nursing. 2010;10(2):231-9. https://doi.org/10.5388/jkon.2010.10.2.231
  10. Berger T, Malayeri R, Doppelbauer A, Krajnik G, Huber H, Auff E, et al. Neurological monitoring of neurotoxicity induced by paclitaxel/cisplatin chemotherapy. Eur J Cancer. 1997;33(9):1393-9. https://doi.org/10.1016/S0959-8049(97)00103-2
  11. Forsyth PA, Balmaceda C, Peterson K, Seidman AD, Brasher P, DeAngelis LM, et al. Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing. J Neurooncol. 1997;35(1):47-53. https://doi.org/10.1023/A:1005805907311
  12. Du Bois A, Schlaich M, Luck HJ, Mollenkopf A, Wechsel U, Rauchholz M, et al. Evaluation of neurotoxicity induced by paclitaxel second-line chemotherapy. Support Care Cancer. 1999;7(5):354-61. https://doi.org/10.1007/s005200050275
  13. Kim JH, Choi KS, Kim TW, Hong YS. Quality of life in colorectal cancer patients with chemotherapy-induced peripheral neuropathy. Asian Oncology Nursing. 2011;11(3):254-62. https://doi.org/10.5388/jkon.2011.11.3.254
  14. Kim HY, Kang JH, Youn HJ, So HS, Song CE, Chae SY, et al. Reliability and validty of the Korean version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire to assess chemotherapy-induced peripheral neuropathy. J Korean Acad Nurs. 2014;44(6):735-42. https://doi.org/10.4040/jkan.2014.44.6.735
  15. Tofthagen CS, McMillan SC, Kip KE. Development and psychometric evaluation of the chemotherapy-induced peripheral neuropathy assessment tool. Cancer Nurs. 2011;34(4):E10-20. https://doi.org/10.1097/NCC.0b013e31820251de
  16. Usha KM, Jayantee K, Pradeep PN. Diagnostic approach to peripheral neuropathy. Ann Indian Acad Neurol. 2008;11(2):89-97. https://doi.org/10.4103/0972-2327.41875
  17. Available at: URL: http://www.questdiagnostics.com/testcenter/testguide.action?dc=WP_LabDiagnosis_PeripheralNeurop#ImmuneMediatedPeripheralNeuropathies.
  18. Thomas N. Seyfried, Roberto E. Flores, Angela M. Poff, Dominic P.D'Agostino. Cancer as a Metabolic Disease. Carcinogenesis. 2014;35(3):515-27. https://doi.org/10.1093/carcin/bgt480
  19. Lord RS, Bralley JA. Laboratory evaluations for integrative and functional medicine. Duluth. GA:Metametrix Institute. 2008.
  20. Orgacka h, Zbytniewski Z. Excretion of vanillic acid and homovanillic acid and tissue distribution of catecholamines and their metabolites in mice with various levels of pigmentation. Endocrinol Pol. 1991;42(3):471-9.